Neurocrine Biosciences, Inc.

Total Valuation

Neurocrine Biosciences, Inc. carries a market capitalization of 16.60B, placing it among publicly traded companies globally. Its enterprise value stands at 12.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Neurocrine Biosciences, Inc. currently has 100.58M shares outstanding.

Valuation Ratios

Neurocrine Biosciences, Inc. trades at a trailing price-to-earnings ratio of 19.64. The price-to-sales ratio is 4.23, and the price-to-book ratio stands at 22.27.

Enterprise Valuation

On an enterprise value basis, Neurocrine Biosciences, Inc. trades at an EV/EBITDA multiple of 14.75 and an EV/FCF ratio of 14.15. The EV/Sales ratio of 3.94 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.30 provides insight into valuation relative to core operating earnings.

Financial Position

Neurocrine Biosciences, Inc. maintains a current ratio of 2.93, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Neurocrine Biosciences, Inc. posts a return on equity of 428.71 and a return on invested capital of 16.26.

Taxes

Over the trailing twelve months, Neurocrine Biosciences, Inc. has paid 268.90M in income taxes, reflecting an effective tax rate of 28.68.

Stock Price Statistics

Neurocrine Biosciences, Inc.'s stock has gained approximately 32.088% over the past 52 weeks. The 50-day moving average sits at 140.08, while the 200-day moving average is 139.74.

Income Statement

Over the trailing twelve months, Neurocrine Biosciences, Inc. generated 3.10B in revenue and converted that into 668.60M in net income, yielding earnings per share of 6.51. EBITDA reached 828.60M, while operating income came in at 798.80M.

Balance Sheet

Neurocrine Biosciences, Inc. holds 1.32B in cash and equivalents against 406.20M in total debt, resulting in a net debt position of -266.50M. Total book value stands at 589.70M, with working capital of 1.60B providing operational flexibility.

Cash Flow

Neurocrine Biosciences, Inc. produced 863.70M in operating cash flow over the past twelve months.

Margins

Neurocrine Biosciences, Inc. operates with a gross margin of 98.17, reflecting its pricing power and cost economics. The operating margin of 25.75 and net profit margin of 21.55 provide insight into operational efficiency.

Dividends & Yields

Scores

Neurocrine Biosciences, Inc. posts an Altman Z-Score of 6.99, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.